Timing of antiviral therapy in patients with hepatitis B virus related hepatocellular carcinoma undergoing hepatectomy
作者机构：Department of GastroenterologyChanghai HospitalNaval Medical UniversityShanghai 200433China Department of Gastroenterology72th Group Army HospitalHuzhou 313000Zhejiang ProvinceChina
出 版 物：《World Journal of Clinical Oncology》 (世界临床肿瘤学杂志（英文版）)
年 卷 期：2024年第15卷第9期
页 面：1251-1255页
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
主 题：Hepatocellular carcinoma Hepatitis B virus Hepatectomy Antiviral therapy Hepatitis B virus-DNA Hepatitis B virus-DNA
摘 要：Globally,hepatocellular carcinoma(HCC)is among the most prevalent and deadly *** B virus(HBV)infection is an important etiology and disease progression factor for *** is a widely accepted curative treatment for HCC,but the long-term survival rate is still unsatisfactory due to the high recurrence rate after *** or postoperative antiviral therapy plays an important role in improving the prognosis for HBV-related HCC patients who underwent ***,many patients miss out on the chance to receive long-term preoperative antiviral medication because their HBV and HCC infections are discovered concurrently,necessitating the start of remedial antiviral therapy in the perioperative ***,it is of great value to know when antiviral therapy is more appropriate and whether perioperative rescue antiviral therapy can achieve the effect of preoperative long-term antiviral therapy.
维普期刊数据库